Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 111

1.

Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event.

Karfis I, Marin G, Machiels G, Hendlisz A, Flamen P.

Clin Nucl Med. 2018 May 14. doi: 10.1097/RLU.0000000000002118. [Epub ahead of print]

PMID:
29762236
2.

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.

Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Marechal R, Galdon MG, Heimann P, Paesmans M, Flamen P, Hendlisz A.

Oncotarget. 2018 Apr 3;9(25):17756-17769. doi: 10.18632/oncotarget.24879. eCollection 2018 Apr 3.

3.

Total choline quantification measured by 1H MR spectroscopy as early predictor of response after neoadjuvant treatment for locally advanced breast cancer: The impact of immunohistochemical status.

Drisis S, Flamen P, Ignatiadis M, Metens T, Chao SL, Chintinne M, Lemort M.

J Magn Reson Imaging. 2018 Apr 16. doi: 10.1002/jmri.26042. [Epub ahead of print]

PMID:
29659077
4.

Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study.

Lemaire M, Lucidi V, Bouazza F, Katsanos G, Vanderlinden B, Levillain H, Delatte P, Garcia CA, Vouche M, Galdon MG, Demetter P, Deleporte A, Hendlisz A, Flamen P, Donckier V.

HPB (Oxford). 2018 Feb 24. pii: S1365-182X(18)30016-9. doi: 10.1016/j.hpb.2018.01.006. [Epub ahead of print]

PMID:
29486918
5.

Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma.

Vouche M, Degrez T, Bouazza F, Delatte P, Galdon MG, Hendlisz A, Flamen P, Donckier V.

World J Hepatol. 2017 Dec 28;9(36):1372-1377. doi: 10.4254/wjh.v9.i36.1372.

6.

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.

Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G.

Oncotarget. 2017 Apr 10;8(34):56185-56198. doi: 10.18632/oncotarget.17015. eCollection 2017 Aug 22.

7.

Unusual diffuse liver 18F-FDG uptake in melanoma patient treated by ipilimumab.

Muteganya R, Karfis I, Artigas C, Garcia C, Francesco F, Kerger J, Flamen P.

Hell J Nucl Med. 2017 May-Aug;20(2):179-181. doi: 10.1967/s002449910562. Epub 2017 Jul 12.

8.

Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review.

Sangro B, Martínez-Urbistondo D, Bester L, Bilbao JI, Coldwell DM, Flamen P, Kennedy A, Ricke J, Sharma RA.

Hepatology. 2017 Sep;66(3):969-982. doi: 10.1002/hep.29207. Epub 2017 Jul 27. Review.

PMID:
28407278
9.

Value of the 68Ga-DOTATATE PET-CT in the diagnosis of endometriosis. A pilot study.

Fastrez M, Artigas C, Sirtaine N, Wimana Z, Caillet M, Rozenberg S, Flamen P.

Eur J Obstet Gynecol Reprod Biol. 2017 May;212:69-74. doi: 10.1016/j.ejogrb.2017.03.022. Epub 2017 Mar 16.

PMID:
28342392
10.

Vertebral Hemangioma Mimicking Bone Metastasis in 68Ga-PSMA Ligand PET/CT.

Artigas C, Otte FX, Lemort M, van Velthoven R, Flamen P.

Clin Nucl Med. 2017 May;42(5):368-370. doi: 10.1097/RLU.0000000000001631.

PMID:
28319497
11.

Accuracy of FDG-PET/CT in Colorectal Peritoneal Carcinomatosis: Potential Tool for Evaluation of Chemotherapeutic Response.

Liberale G, Lecocq C, Garcia C, Muylle K, Covas A, Deleporte A, Hendlisz A, Bouazza F, El Nakadi I, Flamen P.

Anticancer Res. 2017 Feb;37(2):929-934.

PMID:
28179354
12.

Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy.

Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Flamen P, Vandenberghe S.

EJNMMI Phys. 2017 Dec;4(1):7. doi: 10.1186/s40658-017-0174-7. Epub 2017 Jan 26.

13.

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.

Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.

BJU Int. 2017 Aug;120(2):197-203. doi: 10.1111/bju.13739. Epub 2017 Jan 4.

PMID:
27981732
14.

Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians.

Van Cutsem E, Verheul HM, Flamen P, Rougier P, Beets-Tan R, Glynne-Jones R, Seufferlein T.

Cancers (Basel). 2016 Aug 31;8(9). pii: E81. doi: 10.3390/cancers8090081. Review.

15.

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.

Woff E, Hendlisz A, Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, Flamen P.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1792-801. doi: 10.1007/s00259-016-3365-x. Epub 2016 Apr 12.

16.

Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.

Gebhart G, Flamen P, De Vries EG, Jhaveri K, Wimana Z.

J Nucl Med. 2016 Feb;57 Suppl 1:81S-8S. doi: 10.2967/jnumed.115.157941. Review.

17.

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P.

Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23.

PMID:
26598545
18.

Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.

Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, Van Velthoven R, Flamen P.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):195-6. doi: 10.1007/s00259-015-3236-x. Epub 2015 Oct 27. No abstract available.

PMID:
26502983
19.

The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.

Hendlisz A, Deleporte A, Delaunoit T, Maréchal R, Peeters M, Holbrechts S, Van den Eynde M, Houbiers G, Filleul B, Van Laethem JL, Ceyssens S, Barbuto AM, Lhommel R, Demolin G, Garcia C, El Mansy H, Ameye L, Moreau M, Guiot T, Paesmans M, Piccart M, Flamen P.

PLoS One. 2015 Sep 30;10(9):e0138341. doi: 10.1371/journal.pone.0138341. eCollection 2015.

20.

Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data.

Paesmans M, Garcia C, Wong CY, Patz EF Jr, Komaki R, Eschmann S, Govindan R, Vansteenkiste J, Meert AP, de Jong WK, Altorki NK, Higashi K, Van Baardwijk A, Borst GR, Ameye L, Lafitte JJ, Berghmans T, Flamen P, Rami-Porta R, Sculier JP.

Eur Respir J. 2015 Dec;46(6):1751-61. doi: 10.1183/13993003.00099-2015. Epub 2015 Sep 24.

Supplemental Content

Loading ...
Support Center